Current and Future Opportunities for Improving Translational Safety
We are delighted to celebrate the third year of our Drug Safety Forum, providing a platform for nonclinical and clinical communities to engage with current safety science and offer a future perspective. We focus on new theoretical and experimental approaches to translational safety science.
The central themes of the forum are two-fold; what more can we achieve and what new models can we access that helps us to better understand what will happen in the clinic. Knowing in vivo testing is still essential, what supplementary data can be gathered to give us a clearer view of clinical safety?
As there is a limited number of places for this symposium. Registration requires a passcode.
If you would like to attend and haven’t yet received a passcode, please contact us at drug.safety.forum@apconix.com
Programme:
The format includes talks, discussion and debates, ensuring the patient remains at the centre of our thinking.
| Time | Title | Speaker |
| 9:00-9:45 | Arrival and Registration | |
| 9:45-10:00 |
Introduction |
Dr Richard Knight, ApconiX |
| Opening Keynote | ||
| 10:00-10:30 | Data science in translational drug safety | Professor Ruth Roberts, ApconiX |
| Morning Session | ||
| 10:30-11:00 | Good Metrics Won’t Save Lives | Dr Layla Hosseini-Gerami, Ignota Labs |
| 11:00-11:30 | Validation and application of NAMs for developmental toxicity testing to predict human safety | Dr José M. Horcas Nieto, Toxys |
| 11:30-12:00 | Structure activity relationships to help avoid ion channel-related CNS liability | Dr Louisa Zolkiewski, ApconiX |
| 12:00-12:30 | Panel Discussion | NAMs and Decision Making: Where Are We? |
| 12:30-13:30 | Lunch Break | |
| Afternoon Session | ||
| 13:30-14:00 | Accelerating Drug Development: Translational PK/PD Modelling for Clinical Success | Jake Dickinson, Seda Pharmaceutical Development Services |
| 14:00-14:30 | Immunogenicity in drug safety | Dr Sean Hammond, ApconiX |
| 14:30-15:00 | Coffee/Tea | |
| 15:00-15:30 | How to build a robust weight of evidence for ICHS1B carcinogenicity assessment | Dr Richard Haworth, RosettaPath |
| 15:30-16:00 | Bridging the Gap: Advancing Translational Safety Through ICH S7B, S7A, and Secondary Pharmacology | Dr Jean-Pierre Valentin, UCB Biopharma SRL |
| 16:00 | Panel Discussion | Nonclinical-Clinical Translation: What Are the Current Challenges? |